Millie D. Long, MD: Expanding the Safety Data on Ustekinumab
New data suggests there is no connection between ustekinumab and the risk of malignancies.
Paul Feuerstadt, MD: The Future of C Difficile Treatment
There are several companies preparing new treatments for recurrent C difficile infections.
Kanika Sehgal, MBBS: The State of C Difficile Care
There are several potential treatments on the horizon for C difficile infections.
Sleep Pharmacotherapy, Melatonin, and the Link to Substance Use Disorders
Gina Poe, PhD, discusses the potential role of beta blockers in treating psychiatric illness-related sleep, as well as the specific benefit of melatonin.
Mental Health Disparities Among the Hispanic Population
NIDA research director Carlos Blanco-Jerez, MD, PhD, reviews how stigma, language barriers and digital health create disparate outcomes in mentally-ill Hispanic patients.
The New Era of Borderline Personality Disorder Care
Lois Choi-Kain, MD, MEd, discusses her field's interest in improving the modern diagnosis and evidenced-based treatment of personality disorders.
Gina Poe, PhD: How Psychiatric Diseases Impact Sleep Health
The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.
Millie Long, MD: The Safety of Ustekinumab
Patients treated with ustekinumab are not at an increased risk of malignancies.
Nora D. Volkow, MD: The Pain Crisis, and Optimizing Addiction Care Delivery
The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.
Identifying and Treating Adolescent Borderline Personality Disorder
Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.
The Psychiatry Blueprint to Retaining Diverse Trainees, Treating Disparity
The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.
Paul Feuerstadt, MD: New Data on RBX2660 at DDW 2022
There are several live microbiota therapeutics in development, including RBX2660.
Bruce Sands, MD: Safety of Ustekinumab Among Bionaive Patients with IBD
Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.
Jean-Frederic Colombel, MD: Promising Data on Upadacitinib for Crohn's Disease
The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.
Challenges in Psychiatry Patient Disparities and Caregiver Representation
Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.
Aasma Shaukat, MD, MPH: Better Detection on Colonoscopies
The age of screening for colon cancer has decreased in recent years.
The Ketamine & Esketamine Care Teams, and Necessary Monitoring
With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.
Blood Biomarkers, Aducanumab and Setting Precedent for Dementia Care Advances
Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.
Nora D. Volkow, MD: Combating COVID-Era Issues in Substance Use Disorder
The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.
The Challenges to Identifying Dementia, Alzheimer-Risk Patients
Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.
Guiding Appropriate Ketamine, Esketamine Use in Psychiatry
The lead author of treatment recommendations weighs in on their current use and future research.
Taha Qazi, MD: Male Sexual Dysfunction Following Ulcerative Colitis Surgery
Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.
How Evolving Psychiatric Definitions Set the Tone for Care
Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.
Adjunctive Cariprazine with Antidepressants Benefits Adult Major Depressive Disorder
New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.
How Mental Illness Definitions Are Still Being Uncovered and Refined
Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.
The Pediatric Disaster Psychiatry Care Team
Linda Chokroverty, MD, discusses the significance of timing, communication and care coordination when children are affected by disasters or trauma.
Understanding Socially-Determined Mental Health and the Impact of COVID-19
APA president-elect Rebecca W. Brendel, MD, JD, discusses the need to prepare for a "twin mental health pandemic" while continuing to appropriately facilitate innovations in psychiatric care.
Zuranolone Benefits Major Depression, Postpartum Depression in Clinical Program
Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.
The Need for Disaster Psychiatry Care
Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.
Eco-Anxiety and Contributing Mental Health Factors Among BIPOC
A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.
